Imagine a high-tech pregnancy test, but for Alzheimer's. Instead of waiting for expensive brain scans, this tool uses a super-thin layer of carbon called graphene to spot tiny warning signs in a drop of blood. It acts like a molecular magnet that catches specific proteins to tell doctors if someone is in the very early stages of memory loss.
Early diagnosis of Alzheimer's is currently difficult, expensive, and invasive, leading to missed opportunities for early intervention in patients with mild cognitive impairment.
A graphene-based PoC IVD system including optimized DNA aptamers, biosensor prototypes, and an AI-supported digital interface.
If you are a diagnostic company dealing with the slow turnaround of lab-based dementia tests — this project developed a graphene-enabled PoC system that identifies up to 5 biomarkers in real-time. This allows for immediate results in primary care settings.
If you are a software firm dealing with complex medical data interpretation — this project developed a digital interface and AI implementation that translates raw biosensor data into clear metrics for healthcare professionals.
If you are a biotech firm dealing with low sensitivity in blood-based sensors — this project developed a surface chemistry combining nano and DNA technologies to improve biocompatibility and specificity.
Based on available project data, the system is designed to be cost-effective, though specific price points are not provided.
The project involves 4 industrial partners and 3 SMEs, suggesting a focus on scalability, but specific manufacturing volumes are not mentioned.
Based on available project data, the project is currently in the development and pilot phase; licensing terms are not specified.
The system is designed for primary healthcare settings and will be demonstrated in 3 clinical centres in Europe.
The project period runs from 2023-10-01 to 2027-09-30, indicating the development and pilot phase ends in late 2027.
The consortium is well-balanced for commercialization, featuring 11 partners across 8 countries. With a 36% industry ratio (4 companies, including 3 SMEs), there is a strong link between the 5 universities and the market. The inclusion of clinical centres in Finland, Greece, and Germany ensures the technology is validated in real-world medical environments.
Contact UNIVERZITA PALACKEHO V OLOMOUCI
Contact us to explore licensing opportunities for graphene-based biosensors.
